Market Overview

UPDATE: Jefferies Raises PT to $20 on Arena Pharmaceuticals on Belviq FDA Aproval

Share:
Related ARNA
Smoke Rising: As More States Legalize, Marijuana Investing Opportunity Grows
Watch These 5 Huge Call Purchases In Thursday Trade
Healthcare bounces back from Trump tantrum (Seeking Alpha)

Jefferies reiterates its Buy rating on Arena Pharmaceuticals (NASDAQ: ARNA) and raises its price target from $9 to $20.

Jefferies says, "Belviq has been approved by the FDA. We believe the Belviq label is a major positive for ARNA, as it lacks a restrictive REMS or cardiovascular monitoring requirements. We remain buyers of ARNA and are raising our price target from $9 to $20."

ARNA closed at $11.39 on Wednesday.

Latest Ratings for ARNA

DateFirmActionFromTo
Sep 2016FBR CapitalInitiates Coverage onOutperform
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & Co.Initiates Coverage onMarket Perform

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!